Allergan Licenses Neurotoxin from Korean Upstart Medytox
By Shannon Ellis
Friday, October 4, 2013
SHANGHAI – While it works to maintain its dominant market share, the U.S.-based maker of Botox (onabotulinumtoxinA) has licensed a promising neurotoxin from a South Korean company.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.